Crewe Advisors LLC Novo Nordisk A S Transaction History

Crewe Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$122.71 - $146.91 $75,589 - $90,496	616 Added 156.74%	1,009 $144,000
Q1 2024 May 13, 2024	BUY	$102.11 - $135.92 $40,129 - $53,416	393 New	393 $50,000
Q3 2023 Nov 08, 2023	BUY	$90.94 - $199.54 $26,463 - $58,066	291 Added 938.71%	322 $29,000
Q2 2023 Jul 28, 2023	SELL	$155.98 - $172.65 $57,868 - $64,053	-371 Reduced 92.29%	31 $5,000
Q1 2023 May 12, 2023	SELL	$132.34 - $159.14 $28,982 - $34,851	-219 Reduced 35.27%	402 $63,000
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $12,005 - $14,733	126 Added 25.45%	621 $62,000
Q2 2022 Aug 02, 2022	BUY	$103.24 - $121.81 $51,103 - $60,295	495 New	495 $55,000
Q4 2021 Feb 10, 2022	SELL	$95.88 - $117.08 $4,314 - $5,268	-45 Closed	0 $0
Q1 2021 Apr 21, 2021	SELL	$67.06 - $75.82 $12,137 - $13,723	-181 Reduced 80.09%	45 $3,000
Q3 2020 Oct 13, 2020	BUY	$63.69 - $70.22 $14,393 - $15,869	226 New	226 $16,000
Q3 2018 Nov 13, 2018	SELL	$46.76 - $51.24 $10,287 - $11,272	-220 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$44.29 - $50.42 $9,743 - $11,092	220 New	220 $10,000

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Crewe Advisors LLC with notifications on news.